EUVIMEDEUVIMED entdecken
Crossref

Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Oren Pasvolsky, Rima M Saliba, Uday R Popat, Amin Alousi, Rohtesh Mehta, Jason Yeh, Gheath Al-Atrash, Masood Adeel, Jeremy Ramdial, David Marin, Gabriela Rondon, Partow Kebriaei und 6 weitere

Clinical Lymphoma Myeloma and Leukemia · 2024-05 · 24 (5) · e196-e204

DOI: 10.1016/j.clml.2024.01.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024-05. Verfasst von Oren Pasvolsky und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Azacitidine, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Antimetabolites, Antineoplastic. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Maintenance after allogeneic hematopoietic cell transplantation (alloHCT) with hypomethylating agents has yielded conflicting results. MATERIALS AND METHODS: We conducted a single center retrospective matched-control analysis with the study group (5-azacitidine [AZA] group) including adults with FLT3-negative acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who received post-transplant AZA maintenance off clinical trial (n = 93). A matched control group was comprised of contemporaneous AML/MDS patients who did not receive any maintenance (n = 357). Primary endpoint was disease progression. RESULTS: The AZA and control groups had comparable patient and disease characteristics except for older age (median: 61 vs. 57 years, P = .01) and lower hematopoietic comorbidity index (median: 2 vs. 3, P = .04) in the AZA group. The 3-year cumulative incidence of progression in the AZA and control groups was 29% vs. 33% (P = .09). The protective effect of AZA on progression was limited to patients with high-risk AML/MDS (HR = 0.4, 95% CI = 0.2-0.8, P = .009). This led to improved progression-free survival both in high-risk AML and MDS patients with maintenance (HR = 0.2, 95% CI = 0.1-0.6, P = .004 and HR = 0.4, 95% CI = 0.2-0.9, P = .04). CONCLUSION: AZA maintenance was associated with a lower progression rate in patients with high-risk FLT3-negative AML or MDS, and AZA maintenance should be considered for post-alloHCT maintenance in this subset.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzacitidineLeukemia, Myeloid, AcuteMyelodysplastic SyndromesAntimetabolites, AntineoplasticMaintenance ChemotherapyDisease ProgressionRetrospective StudiesCase-Control StudiesHumansMaleFemaleAdolescentYoung AdultAdultMiddle AgedAgedHematopoietic Stem Cell TransplantationProgression-Free SurvivalTreatment Outcome

Stichwörter der Autor:innen

AMLHCTMDSallogeneicvidaza

Substanzen

AzacitidineAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
  • Division of Pharmacy, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
  • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX. Electronic address: BOran@mdanderson.org.

Zitieren

APA

Pasvolsky, O., Saliba, R. M., Popat, U. R., Alousi, A., Mehta, R., Yeh, J., Al-Atrash, G., Adeel, M., Ramdial, J., Marin, D., Rondon, G., Kebriaei, P., Champlin, R., Daver, N., Dinardo, C., Short, N. J., Shpall, E. J., & Oran, B. (2024). Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clinical Lymphoma Myeloma and Leukemia, 24(5), e196-e204. https://doi.org/10.1016/j.clml.2024.01.012

Vancouver

Pasvolsky O, Saliba RM, Popat UR, Alousi A, Mehta R, Yeh J, et al. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clinical Lymphoma Myeloma and Leukemia. 2024;24(5):e196-e204. doi:10.1016/j.clml.2024.01.012

BibTeX
@article{Pasvolsky2024,
  author = {Pasvolsky, Oren and Saliba, Rima M and Popat, Uday R and Alousi, Amin and Mehta, Rohtesh and Yeh, Jason and Al-Atrash, Gheath and Adeel, Masood and Ramdial, Jeremy and Marin, David and Rondon, Gabriela and Kebriaei, Partow and Champlin, Richard and Daver, Naval and Dinardo, Courtney and Short, Nicholas J and Shpall, Elizabeth J and Oran, Betül},
  title = {Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  volume = {24},
  number = {5},
  pages = {e196--e204},
  doi = {10.1016/j.clml.2024.01.012}
}
Kostenlos starten →